The US Food & Drug Administration’s newly formed liver drug division is now under the direction of hepatologist with the appointment of Frank Anania as acting director of the Division of Hepatology & Nutrition.
The dedicated liver drug review division was formed as part of the broad reorganization of the Office of New Drugs and launched in 2020, with Joseph Toerner as the acting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?